Fintech PR

Lingang supports foreign companies to achieve high-quality growth in China

Published

6 months ago

November 3, 2023

lingang-supports-foreign-companies-to-achieve-high-quality-growth-in-china

SHANGHAI, Nov. 3, 2023 /PRNewswire/ — The Sixth China International Import Expo (CIIE) will be held from November 5 till 10 in Shanghai. It is not only a platform for exhibitors and purchasers to meet and exchange ideas, but also a great venue for Chinese park operators to show their capabilities and services.

At the Lingang Group Exhibition Hall, the stand of Germany-based Lenze Company has taken up a prime location and caught the eyes of many visitors. “We are very grateful to Lingang Group for providing us with such an amazing stage to launch our new products. This is a great opportunity to introduce us to more clients,” said Li Jin, Senior National Sales Director, Lenze China.

Lenze, which joined CIIE for the first time this year, is a globally leading automation company for mechanical engineering. It invested in Lingang in 2007 and has become “an old friend” of the park ever since.

Since 2019, thanks to the establishment of Lin-gang Special Area of China (Shanghai) Pilot Free Trade Zone, Lenze’s base in the area has grown from a manufacturing site into its second global headquarters as well as the HQ of East Asia, which has R&D, manufacturing and sales functions. The company’s role has also evolved from “In China for China” to “In China for the World”.

The remarkable growth of Lenze in China is just one example of the services that the Lingang Group has provided to foreign investors.

Starting from its earliest days, Lingang Group has adopted a globalized growth mindset. Caohejing Hi-Tech Park, which is one of the industrial parks currently operated by Lingang, has attracted many foreign technology investors since as early as the end of 1980s, such as Philips, AT&T, Air Liquide, 3M and METTLER TOLEDO. Now 144 Global Fortune 500 companies have set up branches in Caohejing, making it one of the most popular destinations for multinational companies to open their regional headquarters and R&D centers in Shanghai.

For an industry park, a high-quality design is a key success factor in attracting investors as well as fostering their future growth.

Lingang Group has worked with UK-based Arlington Park to develop the Caohejing Sci-Tech Oasis Park, a “park-in-park” with globally leading infrastructure and services. In recent years, the group has enhanced its supportive capabilities and facilities for a number of prioritized industries, such as integrated circuits, biomedicine and intelligent manufacturing. By understanding clients’ unique business processes and organizational structure, Lingang is now able to provide them with the most suitable, cost-effective and convenient factories and facilities.

The world-leading heating and air-conditioning solution provider Johnson Controls – Hitachi Air Conditioning is another good example. It has chosen to invest in Lingang Fengxian Park because there is a complete low-carbon green manufacturing industry cluster around the park. The two parties will work together to achieve synergy by powering the growth of companies in the upper and lower streams of this industry chain.

Just as the Lenze case has shown, Lingang’s service has often exceeded the investors’ expectations. During this CIIE, Lingang Group has invited nearly 100 foreign invested companies to join its exhibition hall, many of whom are located in the group’s parks. Lingang has offered customized services to help them build their brand image, capture the opportunities the CIIE has brought, and win more friends as well as clients.

Lingang Group’s excellent services have also propelled the high-quality sustainable development of foreign-invested companies in China. The group has made great efforts to realize its ESG ambition by setting up a “Six Pillar Innovation Supportive Framework”, which focuses on providing an innovation-enabling system for technological, digital, green, service, financial and overseas innovations. The group aims to find a balanced growth pattern to create economic, social and environmental values.

For example, Tesla was given the official permission to start its groundwork in 2018. In 2019, its Gigafactory achieved three remarkable milestones — breaking ground, starting operation and factory delivery — all within one year. In 2020, this factory began to mass produce Model 3 cars and export them to the European market.

Behind this amazing speed is Lingang Group’s high-quality service based on its deep understanding of the area, clients’ industries and their expertise. Elon Musk, the founder of Tesla, has personally praised the surprisingly fast Shanghai speed.

The fast expansion of foreign companies in China is also supported by the institutional reforms undertaken by the areas where Lingang’s parks are located. For example, the Lin-gang Special Area of China (Shanghai) Pilot Free Trade Zone has kept enhancing its level of opening-up since it was established more than four years ago. As a result, the foreign direct investment into this area has maintained an annual growth rate of more than 50%. It has established China’s first comprehensive bonded zone (Yangshan Free Trade Zone) and the first wealth management company controlled by a foreign investor. It is also accelerating the development of international financial asset trading platforms, Shanghai Petroleum and Natural Gas Exchange and the International Board for Reinsurance Trading — just to name a few institutional innovation achievements. It is estimated that by 2025, Lin-gang Pilot Free Trade Zone will host 10,000 overseas talents and will issue more than 3,000 Foreigner’s Work Permits.

The high-quality growth of foreign invested companies will also contribute to Chinese people’s better life quality. This June, Medtronic Inc. began to build its first manufacturing line at Lingang Life Science & Tech Park to better meet the needs of Chinese patients.

“We expect our Lingang project can continue to exceed expectations to better serve not only domestic patients, but also patients in other parts of the world,” said Alex Gu, Senior Vice President and President of Medtronic Greater China.

Image Attachments Links:

Link: https://iop.asianetnews.net/view-attachment?attach-id=443024

Caption: Caohejing Hi-Tech Park

Link: https://iop.asianetnews.net/view-attachment?attach-id=443037

Caption: Lingang Life Science & Tech Park

Photo – https://mma.prnewswire.com/media/2265927/1_Lingang.jpg
Photo – https://mma.prnewswire.com/media/2265926/2_Lingang.jpg

View original content:https://www.prnewswire.co.uk/news-releases/lingang-supports-foreign-companies-to-achieve-high-quality-growth-in-china-301977229.html

Fintech PR

Invitation to presentation of EQT AB’s Q1 Announcement 2024

Published

4 weeks ago

April 5, 2024

CISION (PR Newswire)

STOCKHOLM, April 5, 2024 /PRNewswire/ — EQT AB’s Q1 Announcement 2024 will be published on Thursday 18 April 2024 at approximately 07:30 CEST. EQT will host a conference call at 08:30 CEST to present the report, followed by a Q&A session.

The presentation and a video link for the webcast will be available here from the time of the publication of the Q1 Announcement.

To participate by phone and ask questions during the Q&A, please register here in advance. Upon registration, you will receive your personal dial-in details.

The webcast can be followed live here and a recording will be available afterwards.

Information on EQT AB’s financial reporting

The EQT AB Group has a long-term business model founded on a promise to its fund investors to invest capital, drive value creation and create consistent attractive returns over a 5 to 10-year horizon. The Group’s financial model is primarily affected by the size of its fee-generating assets under management, the performance of the EQT funds and its ability to recruit and retain top talent.

The Group operates in a market driven by long-term trends and thus believes quarterly financial statements are less relevant for investors. However, in order to provide the market with relevant and suitable information about the Group’s development, EQT publishes quarterly announcements with key operating numbers that are relevant for the business performance (taking Nasdaq’s guidance note for preparing interim management statements into consideration). In addition, a half-year report and a year-end report including financial statements and further information relevant for investors is published. Finally, EQT also publishes an annual report including sustainability reporting.

Contact
Olof Svensson, Head of Shareholder Relations, +46 72 989 09 15
EQT Shareholder Relations, [email protected]

Rickard Buch, Head of Corporate Communications, +46 72 989 09 11
EQT Press Office, [email protected], +46 8 506 55 334

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/eqt/r/invitation-to-presentation-of-eqt-ab-s-q1-announcement-2024,c3956826

The following files are available for download:

https://mb.cision.com/Main/87/3956826/2712771.pdf	Invitation to presentation of EQT AB’s Q1 Announcement 2024
https://news.cision.com/eqt/i/eqt-ab-group,c3285895	EQT AB Group

View original content:https://www.prnewswire.co.uk/news-releases/invitation-to-presentation-of-eqt-abs-q1-announcement-2024-302109147.html

Fintech PR

Kia presents roadmap to lead global electrification era through EVs, HEVs and PBVs

Published

4 weeks ago

April 5, 2024

CISION (PR Newswire)

kia-presents-roadmap-to-lead-global-electrification-era-through-evs,-hevs-and-pbvs

Kia drives forward transformation into ‘Sustainable Mobility Solutions Provider’
Roadmap enables Kia to proactively respond to uncertainties in mobility industry landscape, including changes in EV market
Company to expand EV line-up with more models; enhance HEV line-up to manage fluctuation in EV demand
- Goal to sell 1.6 million EVs annually in 2030, introducing 15 models
- PBV to play a key role in Kia’s growth, targeting 250,000 PBV sales annually by 2030 with PV5 and PV7 models
Kia to invest KRW 38 trillion by 2028, including KRW 15 trillion for future business
2024 business guidance : KRW 101 tln in revenue with KRW 12 tln in operating profit; operating profit margin of 11.9% on sales of 3.2 million units globally
CEO reaffirms Kia’s commitment to ESG management

SEOUL, South Korea, April 5, 2024 /PRNewswire/ — Kia Corporation (Kia) today shared an update on its future strategies and financial targets at its CEO Investor Day in Seoul, Korea.

Based on its innovative achievements in the years since the announcement of mid-to-long-term business initiatives, Kia is focusing on updating its 2030 strategy announced last year and further strengthening its business strategy in response to uncertainties across the global mobility industry landscape.

During the event, Kia updated its mid-to-long-term business strategy with a focus on electrification, and its PBV business. Kia reiterated its 2030 annual sales target of 4.3 million units, including 1.6 million units of electric vehicles (EVs). The 2030 4.3 million annual sales target is 34.4 percent higher than the brand’s 2024 annual goal of 3.2 million units.

The company also plans to become a leading EV brand by selling a higher percentage of electrified models among its total sales, including hybrid electric vehicles (HEV), plug-in hybrid (PHEV), and battery EVs, projecting electrified model sales of 2.48 million units annually or 58 percent of Kia’s total sales in 2030.

“Following our successful brand relaunch in 2021, Kia is enhancing its global business strategy to further the establishment of an innovative EV line-up and accelerate the company’s transition to a sustainable mobility solutions provider,” said Ho Sung Song, President and CEO of Kia. “By responding effectively to changes in the mobility market and efficiently implementing mid-to-long-term strategies, Kia is strengthening its brand commitment to the wellbeing of customers, communities, the global society, and the environment.”

Photo – https://mma.prnewswire.com/media/2380039/Photo_1__2024_CEO_Investor_Day.jpg
PDF – https://mma.prnewswire.com/media/2380040/Press_Release__2024_Kia_CEO_Investor_Day_240405.pdf

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/kia-presents-roadmap-to-lead-global-electrification-era-through-evs-hevs-and-pbvs-302109142.html

Fintech PR

BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update

Published

4 weeks ago

April 5, 2024

CISION (PR Newswire)

VANCOUVER, BC, April 4, 2024 /PRNewswire/ — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (the “Company“) is providing this bi-weekly update on the status of the management cease trade order granted on February 29, 2024 (the “MCTO“), by its principal regulator, the Ontario Securities Commission (the “OSC“), under National Policy 12-203 – Management Cease Trade Orders (“NP 12-203“), following the Company’s announcement on February 21, 2024 (the “Default Announcement“), that it was unable to file its audited annual financial statements for the year ended October 31, 2023, its management’s discussion and analysis of financial statements for the year ended October 31, 2023, its annual information form for the year ended October 31, 2023, and related filings (collectively, the “Required Annual Filings“). Under National Instrument 51-102, the Required Annual Filings were required to be made no later than February 28, 2024.

As a result of the delay in filing the Required Annual Filings, the Company was unable to file its interim financial statements for the three months ended January 31, 2024, its management’s discussion and analysis of financial statements for the three months ended January 31, 2024, and related filings (collectively, the “Required Interim Filings“). Under National Instrument 51-102, the Required Interim Filings were required to be made no later than April 1, 2024.

The Company anticipates filing the Required Annual Filings by April 30, 2024. The auditor of the Company requires additional time to complete its audit of the Company, including the Company’s recent acquisition of all intellectual property, immunotherapeutics platform technologies, and clinical stage assets of the former IMV Inc. that closed on February 16, 2024. In addition, the Company anticipates filing the Required Interim Filings immediately after the filing of the Required Annual Filings.

Except as herein disclosed, there are no material changes to the information contained in the Default Announcement. In addition, (i) the Company is satisfying and confirms that it intends to continue to satisfy the provisions of the alternative information guidelines under NP 12-203 and issue bi-weekly default status reports for so long as the delay in filing the Required Annual Filings and/or Required Interim Filings is continuing, each of which will be issued in the form of a press release; (ii) the Company does not have any information at this time regarding any anticipated specified default subsequent to the default in filing the Required Annual Filings and Required Interim Filings; (iii) the Company is not subject to any insolvency proceedings; and (iv) there is no material information concerning the affairs of the Company that has not been generally disclosed.

About BioVaxys Technology Corp.

BioVaxys Technology Corp. (www.biovaxys.com), a biopharmaceuticals company registered in British Columbia, Canada, is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX™ immune-educating technology platform and it’s HapTenix© ‘neoantigen’ tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other immunological fields. The Company’s clinical stage pipeline includes maveropepimut-S which is in Phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using it proprietary HapTenix© ‘neoantigen’ tumor cell construct platform which is soon to enter Phase I in Spain for treating refractive late-stage ovarian cancer. The Company is also capitalizing on its tumor immunology know-how and creation of a unique library of T-lymphocytes & other datasets post-vaccination with its personalized immunotherapeutic vaccines to utilize predictive algorithms and other technologies to identify new targetable tumor antigens. BioVaxys common shares are listed on the CSE under the stock symbol “BIOV” and trade on the Frankfurt Bourse (FRA: 5LB) and in the US (OTCQB: BVAXF). For more information, visit www.biovaxys.com and connect with us on X and LinkedIn.

ON BEHALF OF THE BOARD

Signed “James Passin“
James Passin, Chief Executive Officer
Phone: +1 646 452 7054

Logo – https://mma.prnewswire.com/media/1430981/BIOVAXYS_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/biovaxys-technology-corp-provides-bi-weekly-mcto-status-update-302108920.html